Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis

Mayo Clinic Proceedings

Volumn 86, Issue 1, 2011, Pages 37-42

  Vaa, Brianna E ^a   Asrani, Sumeet K ^b   Dunn, Winston ^b,c   Kamath, Patrick S ^b   Shah, Vijay H ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c Kansas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; ASCITES; CLINICAL ARTICLE; FEMALE; HUMAN; HYPONATREMIA; INTERMETHOD COMPARISON; MALE; MODEL FOR END STAGE LIVER DISEASE; MODEL FOR END STAGE LIVER DISEASE INCLUDING SODIUM; MORTALITY; SCORING SYSTEM; SENSITIVITY AND SENSIBILITY; SODIUM BLOOD LEVEL; SURVIVAL;

EID: 78650976583     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0281     Document Type: Article

References (25)

1. Paula H, Asrani SK, Boetticher NC, Pedersen R, Shah VH, Kim WR. Alcoholic liver disease-related mortality in the United States: 1980-2003. Am J Gastroenterol. 2010;105(8):1782-1787.
2. Malinchoc M, Kamath P, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864-871.
3. Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: Moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851-858.
4. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: Application of survival models to liver allocation. Liver Transpl. 2001;7(7): 567-580.
5. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-470.
6. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41(2):353-358.
7. Wiesner R, Edwards E, Freeman R, et al; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for End-stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124(1):91-96.
8. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018-1026.
9. Guy J, Somsouk M, Shiboski S, Kerlan R, Inadomi JM, Biggins SW. New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol. 2009; 7(11):1236-1240.
10. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40(4):802-810.
11. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130(6): 1652-1660.
12. Liamis GL, Milionis HJ, Rizos EC, Siamopoulos KC, Elisaf MS. Mechanisms of hyponatraemia in alcohol patients. Alcohol Alcohol. 2000;35(6): 612-616.
13. Somsouk M, Guy J, Biggins SW, Vittinghoff E, Kohn MA, Inadomi JM. Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther. 2009;30(7):741-748.
14. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135(6):1953-1960.
15. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: A randomized multicenter trial. Ann Intern Med. 1989;110(9):685-690.
16. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637-1648.
17. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54(8):1174-1179.
18. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348-1354.
19. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646-1654.
20. Mackle IJ, Swann DG, Cook B. One year outcome of intensive care patients with decompensated alcoholic liver disease. Br J Anaesth. 2006; 97(4):496-498.
21. Pathak OK, Paudel R, Panta OB, Pant HP, Giri BR, Adhikari B. Retrospective study of the clinical profile and prognostic indicators in patients of alcoholic liver disease admitted to a tertiary care teaching hospital in Western Nepal. Saudi J Gastroenterol. 2009;15(3):171-175.
22. Gines P, Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. Hepatology. 2008;48(3):1002-1010.
23. Boyer TD. Tolvaptan and hyponatremia in a patient with cirrhosis. Hepatology. 2010;51(2):699-702.
24. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002;2:2.
25. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758-2769.